Rosemont Pharmaceuticals, which has been active in the development, production, and distribution of liquid pharmaceuticals for over 50 years, has acquired Pharma-Data, a privately held research and development company based in Lavrio, Attica. The financial terms of the deal were not disclosed. 

Pharma-Data specializes in the research & development (R&D) of value-added pharmaceutical products for Europe and the US and has its own research and development design laboratory in Athens, which is certified to Good Manufacturing Practice (GMP) by the National Organization for Medicines (EOF). The company also provides development, dossier writing, technology transfer, licensing, and regulatory services on a global basis, a statement said.

"The acquisition further enhances Rosemont's already extensive in-house product development capability while improving Rosemont's ability to develop other dosage forms and oral slow-release liquids, the announcement of the deal says". 

Howard Taylor, CEO of Rosemont, said: "The acquisition of and access to Pharma-Data is both exciting and significant for Rosemont Pharmaceuticals. Firstly, it reinforces our commitment to developing innovative, patient-centric medicines for patients who cannot swallow tablets, and secondly, it is Rosemont's first step towards expansion through international subsidiaries beyond the UK. Everyone at Rosemont is looking forward to working with the team in Greece."

Yannis Psarrakis, CEO of Pharma-Data, said: "We are excited to join the Rosemont family! We strongly believe that this acquisition will seal our efforts to provide high-quality, value-added medicines and will lead to a multitude of synergies, ensuring that both Rosemont and Pharma-Data will always focus on new therapeutic approaches. We look forward to this new era and working closely with our new colleagues."